Early-stage study of Advaxis' cancer candidate ADXS-NEO underway
Seeking Alpha
Published Jun 11, 2018 10:27AM ET
Early-stage study of Advaxis' cancer candidate ADXS-NEO underway
- The first patient has been dosed in a Phase 1 clinical trial assessing Advaxis' (ADXS) ADXS-NEO, a personalized immunotherapy targeting cancer neoantigens, in patients with metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer.
- Participants will undergo a biopsy. Advaxis will then manufacture a customized treatment based on an analysis of their tumor neoantigen mutations, a process that takes ~eight weeks.
- According to ClinicalTrials.gov, the estimated primary completion date is September 2019.
- The company is co-developing ADXS-NEO with Amgen (AMGN -0.6%), with Advaxis leading development through proof-of-concept.
- Now read: Has A New Advaxis Awakened Out Of The Doldrums?
Original article
Get The News You Want
Written By: Seeking Alpha
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.